HIV Infections
Conditions
Keywords
HIV-I, Reverse transcriptase inhibitors, HIV Seronegativity
Brief summary
The purpose of this trial was to evaluate the safety and feasibility of using a vaginal ring to deliver the candidate microbicide TMC120 (dapivirine). Twelve women initially underwent 7-day exposure to a placebo ring containing no investigational agent. They then underwent 7-day exposure to a ring containing 120 mg of TMC120 (dapivirine). Feasibility was assessed in terms of safety and tolerability as well as drug delivery.
Interventions
vaginal ring containing no TMC120 (dapivirine)
DRUGTMC120 (dapivirine) vaginal ring
vaginal ring containing 120 mg TMC120 (dapivirine)
Sponsors
Tibotec Pharmaceutical Limited
International Partnership for Microbicides, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Female, 18-50 years, inclusive * Willing and able to provide written informed consent * HIV-uninfected and otherwise healthy * Willing to abstain from sexual activity and use of vaginal products while participating in the trial * Currently using oral contraceptives for pregnancy prevention * Willing to use oral contraceptives as needed to avoid menstruation while taking part in this trial
Exclusion criteria
* History of alcoholism, drug abuse, psychosis, antagonistic personality, poor motivation, or other emotional or intellectual problems that are likely to invalidate the informed consent process or adversely impact compliance with protocol requirements. * History of allergy to TMC120 or to the constituents of the vaginal ring. * History of hypersensitivity to propofol, or other contraindication to general anesthesia or sedation * History of diagnosis of and/or treatment for a sexually transmitted disease within the last three months. * History of genital tract surgery within the last month * Currently pregnant or breastfeeding, or within two months of last pregnancy outcome * Currently or within one month of participating in any other clinical research trial * Current (during screening) diagnosis of any genital infection * Current vulvar of vaginal symptoms * Current non-iatrogenic pelvic/colposcopic exam findings involving deep epithelial disruption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TMC120 (dapivirine) concentrations in vaginal fluids, vaginal and cervical epithelial tissue, and plasma | 7 days |
| safety and tolerability of a vaginal ring containing TMC120 (dapivirine) | 7 days |
Countries
Belgium
Outcome results
None listed